{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Fibrin Glue Sealant in Liver Resection"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "300 patients undergoing hepatic resection were randomly assigned"
      },
      "Participants": {
        "score": 1,
        "evidence": "300 patients undergoing hepatic resection"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to receive either fibrin glue application or standard care (control)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was intraoperative blood loss."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved using a computer-generated sequence, with allocation concealment via sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 150 patients were allocated to each group"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "analysis conducted on an intention-to-treat basis"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "No significant differences were found in transfusion requirements (0.15 \u00b1 0.66 vs. 0.17 \u00b1 0.63 PRCU; P = 0.7234)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported in either group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}